Announcement by Servier and Poietis of scientific partnership in 4D bioprinting of liver tissues
Paris and Pessac, France – 19 September 2018 – Servier, an independent international pharmaceutical company, and Poietis, a leader in the production of living bioprinted tissues, have announced a scientific partnership to use Poietis’s 4D bioprinting technology for the development and production of liver tissues.
This partnership seeks to improve the detection of drug-induced liver lesions as early as the preclinical trial phase. Such lesions are rare1 but can have serious consequences for patients. This hepatotoxic2 potential is poorly detected by current preclinical models. Beyond animal models, various models based on human cell cultures are available, but most lack longevity and complexity, which limits their usefulness in toxicology. Poietis’s 4D bioprinting technology has emerged as an innovative technology capable of helping to overcome these limitations. Continue reading “Announcement by Servier and Poietis of scientific partnership in 4D bioprinting of liver tissues”